Effects of long-term antipsychotics treatment on body weight: A population-based cohort study
- PMID: 31724905
- PMCID: PMC6947810
- DOI: 10.1177/0269881119885918
Effects of long-term antipsychotics treatment on body weight: A population-based cohort study
Abstract
Background: Antipsychotics are often prescribed for long-term periods, however, most evidence of their impact on body weight comes from short-term clinical trials. Particularly, impact associated with dosage has been barely studied.
Aims: The aim of this study was to describe the short- and long-term change in body weight of people initiated on high or low doses of the three most commonly prescribed second-generation antipsychotics.
Methods: Retrospective cohorts of individuals with a diagnosed psychotic disorder observed from 2005 to 2015 in the UK primary care. The exposure was the first prescription of olanzapine, quetiapine or risperidone. The main outcome was change in body weight four years before and four years after initiation of antipsychotic treatment, stratified on sex and 'low' or 'high' dose.
Results: In total, 22,306 women and 16,559 men were observed. Olanzapine treatment was associated with the highest change in weight, with higher doses resulting in more weight gain. After 4 years, given a high dose of olanzapine (> 5 mg), women gained on average +6.1 kg; whereas given a low dose (⩽ 5 mg), they gained +4.4 kg. During the first six weeks of olanzapine treatment, they gained on average +3.2 kg on high dose and +1.9 kg on low dose. The trends were similar for men. Individuals prescribed risperidone and quetiapine experienced less weight gain in both the short- and long-term.
Conclusions: Olanzapine treatment was associated with the highest increase in weight. Higher doses were associated with more weight gain. Doctors should prescribe the lowest effective dose to balance mental-health benefits, weight gain and other adverse effects.
Keywords: Antipsychotic agents; dopamine; electronic health records; interrupted time series analysis; noradrenaline; serotonin; weight gain.
Conflict of interest statement
Figures


Similar articles
-
Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database.J Psychopharmacol. 2018 Oct;32(10):1098-1103. doi: 10.1177/0269881118780011. Epub 2018 Jun 25. J Psychopharmacol. 2018. PMID: 29938561
-
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.Int J Neuropsychopharmacol. 2020 Apr 23;23(4):217-229. doi: 10.1093/ijnp/pyaa004. Int J Neuropsychopharmacol. 2020. PMID: 31974576 Free PMC article. Clinical Trial.
-
Long-term metabolic side effects of second-generation antipsychotics in Chinese patients with schizophrenia: A within-subject approach with modelling of dosage effects.Asian J Psychiatr. 2024 Oct;100:104172. doi: 10.1016/j.ajp.2024.104172. Epub 2024 Aug 3. Asian J Psychiatr. 2024. PMID: 39128294
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
-
An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Hum Psychopharmacol. 2011. PMID: 23055416 Review.
Cited by
-
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.Schizophr Bull. 2022 May 7;48(3):643-654. doi: 10.1093/schbul/sbac001. Schizophr Bull. 2022. PMID: 35137229 Free PMC article.
-
Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis.Neuropsychiatr Dis Treat. 2023 Oct 26;19:2295-2308. doi: 10.2147/NDT.S426481. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 37908559 Free PMC article.
-
Predicting maintenance lithium response for bipolar disorder from electronic health records-a retrospective study.PeerJ. 2024 Oct 14;12:e17841. doi: 10.7717/peerj.17841. eCollection 2024. PeerJ. 2024. PMID: 39421428 Free PMC article.
-
Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000-2019: 20-year investigation of who receives treatment, with which agents and at what doses.Br J Psychiatry. 2024 Dec 18;226(5):1-9. doi: 10.1192/bjp.2024.186. Online ahead of print. Br J Psychiatry. 2024. PMID: 39690823 Free PMC article.
-
Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments.BMC Psychiatry. 2022 Mar 21;22(1):210. doi: 10.1186/s12888-022-03853-y. BMC Psychiatry. 2022. PMID: 35313842 Free PMC article.
References
-
- Blak BT, Thompson M, Dattani H, et al. (2011) Generalisability of The Health Improvement Network (THIN) database: Demographics, chronic disease prevalence and mortality rates. Inform Prim Care 19: 251–255. - PubMed
-
- Bushe CJ, Slooff CJ, Haddad PM, et al. (2012) Weight change from 3-year observational data: Findings from the worldwide schizophrenia outpatient health outcomes database. J Clin Psychiatry 73: e749–e755. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical